faxeladol
Faxeladol is an opioid analgesic which was developed by Grünenthal GmbH but was never marketed for medical use anywhere in the world. It is related to tramadol and ciramadol, and was developed shortly after tramadol in the late 1970s. Similarly to tramadol, it was believed faxeladol would have analgesic, as well as antidepressant effects, due to its action on serotonin and norepinephrine reuptake. In various studies in the 1970s alongside tramadol, faxeladol was seen to be slightly more potent than tramadol, but with a higher rate of sudden seizures than tramadol, which is known to cause seizures without warning in some users. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Oct 22, 2003 (NCT03765801)
Timeline
Indications
Mechanism of action
- Mu opioid receptorAGONIST
OPRM agonist
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
Chemistry & pharmacology
SMILES
CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1- Mol. weight
- 233.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFaxeladol ↗
- ChEMBLCHEMBL2103829 ↗
Also known as
- em-906
- em-906
- faxeladol
- faxeladol
- gcr-9905
- gcr-9905
- grt-9906
- grt-9906
- grta0009906
- grta0009906
- grta9906
- grta9906
- grt-ta300
- grt-ta300
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03783910 | Phase 2 | Sep 19, 2005 | Grunenthal |
| NCT03776110 | Phase 1 | Sep 15, 2004 | Grunenthal |
| NCT03765801 | Phase 1 | Oct 22, 2003 | Grunenthal |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Grunenthal | For profit | 3 | 3 | 2 | 2003 |